Bristol Myers Squibb Shares Rise on Positive Phase 3 Trial Results
Bristol Myers Squibb's stock rose nearly 6% in premarket trading after announcing positive topline results from two late-stage clinical trials. The ALOFT-IPF trial, testing admilparant for idiopathic pulmonary fibrosis (IPF), met its primary endpoint. Another Phase 3 study also showed favorable outcomes. The results suggest potential therapeutic advancements and could support regulatory submissions or commercialization efforts in the near future. These developments are seen as a positive sign by investors, reflecting progress in Bristol Myers' drug development pipeline for respiratory diseases.
Tickers: $BMY
Topics: drug_development ipf pharma